Grants per year
Fingerprint
Dive into the research topics where Cancer is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research & Focus Areas
Profiles
-
Neuro-exergaming for the Prevention and Remediation of Decline due to Parkinson's Disease: Clinical Trial of the Interactive Physical and Cognitive Exercise System (iPACES v3)
Gillen, R. R. W., Anderson-hanley, C., Merrill, D., Saulnier, E. E., Molho, E. E. S., Arciero, J. P., Petrossian, M. M., Arciero, P. P. J., Panos, S. E. & Clark, S. S.
National Institute of Neurological Disorders and Stroke
08/11/23 → 07/31/24
Project: Research
-
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
Cobbs, C. & Searle, B. B. C.
01/1/23 → 12/31/24
Project: Research
-
DNASE1L3 regulation of anti-tumor immune responses following radiation therapy
01/1/23 → 12/31/24
Project: Research
Research Output
-
Advances and challenges in cancer immunoprevention and immune interception
Stanton, S. E., Castle, P. E., Finn, O. J., Sei, S. & Emens, L. A., Mar 21 2024, In: Journal for ImmunoTherapy of Cancer. 12, 3Research output: Contribution to journal › Review article › peer-review
Open Access -
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
Beckermann, K. E., Bestvina, C. M., El Osta, B., Sanborn, R. E., Borghaei, H., Lammers, P. E., Selvaggi, G., Whisenant, J. G., Heimann-Nichols, E., Berry, L., Hsu, C. Y., Shyr, Y., Horn, L. & Wakelee, H., Feb 2024, In: JTO Clinical and Research Reports. 5, 2, 100619.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators, Jan 6 2024, In: The Lancet. 403, 10421, p. 31-43 13 p.Research output: Contribution to journal › Article › peer-review
8 Scopus citations